Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues

Giornale Italiano di Dermatologia e Venereologia

Volumn 145, Issue 2, 2010, Pages 245-258

  Quinn, T ^a   Zhang, X ^a   Miao, Y ^b  

^a University of Missouri   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Alpha MSH; Diagnostic imaging; Melanoma; Peptides; Tomography, emission computed, single photon

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CYSTEINYLCYSTEINYLNORLEUCYL DEXTRO PHENYLALANYLCYSTEINYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CYSTEINYLCYSTEINYLNORLEUCYL DEXTRO PHENYLALANYLCYSTEINYLARGINYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GLYCYLGLUTAMYLLYSYLNORLEUCYL DEXTRO PHENYLALANYLARGINYLASPARTYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LYSYLNORLEUCYL DEXTRO PHENYLALANYLARGINYLASPARTYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID N ACETYL ASPARTYLNORLEUCYL DEXTRO PHENYLALANYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID N ACETYL BETA ALANYLNORLEUCYL DEXTRO PHENYLALANYLLYSYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NORLEUCYL DEXTRO PHENYLALANYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID RHENIUM ARGINYL CYSTEINYLCYSTEINYLNORLEUCYL DEXTRO PHENYLALANYLCYSTEINYLARGINYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVAL LU 177; 4,11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE CYSTEINYLCYSTEINYLNORLEUCYL DEXTRO PHENYLALANYLCYSTEINYLARGINYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTYL DEXTRO TYROSYLASPARTYLLYSYLCYSTEINYLCYSTEINYLNORLEUCYL DEXTRO PHENYLALANYLCYSTEINYLARGINYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; DISULFIDE; LYSINE; MELANOCORTIN 1 RECEPTOR; N ACETYL IODINE 125 TYROSYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; N ACETYL IODINE 125 TYROSYLNORLEUCYL DEXTRO PHENYLALANYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; N ACETYL IODINE 125 TYROSYLNORLEUCYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; N ACETYL LYSYLCYSTEINYLCYSTEINYLNORLEUCYL DEXTRO PHENYLALANYLCYSTEINYLARGINYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; N ACETYL NORLEUCYL DEXTRO PHENYLALANYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; PLACEBO; RADIOPHARMACEUTICAL AGENT; RHENIUM 188 ARGINYL CYSTEINYLCYSTEINYLNORLEUCYL DEXTRO PHENYLALANYLCYSTEINYLARGINYL N ACETYL SERYLTYROSYLSERYLMETHIONYLGLUTAMYLHISTIDYLPHENYLALANYLARGINYLTRYPTOPHYLG LYCYLLYSYLPROLYLVALINAMIDE; UNCLASSIFIED DRUG;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CYCLIZATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA B16; MOLECULAR WEIGHT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIATION DOSE; REVIEW; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN PIGMENTATION; TUMOR CELL; TUMOR GROWTH;

EID: 77954517615     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Morton DL, Wen R, Wong JH, Economou JS, Cagle LA, Sorm FK et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
2. Mariani G, Gipponi M, Moresco L, Villa G, Bartolomei M, Mazzarol G et al. Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. J Nucl Med 2002;43:811-27.
3. Hoffman U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients: monocenter evaluation of methods, cost, and patient survival. Br J Cancer 2002;87:151-7.
4. 99mTc-MIBI Scintigraphy. J Nucl Med 2003;44:1561-5.
5. Sabel MS. Wong SL. Review of evidence-based support for pretreatment imaging in melanoma. J Natl Comprehensive Cancer Network 2009;7:281-9.
6. 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508.
7. Iagaru A, Quon A, Johnson D, Gambhir SS, McDougall IR. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol 2007;9:50-7.
8. 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001;91:1530-42.
9. Constantinidou A, Hofman M, O'Doherty M, Acland KM, Healy C, Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Research 2008;8:56-60.
10. Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clinical Oncology 2001;19:2674-8. (Pubitemid 32441372)
11. Krug B, Dietlein M, Groth W, Strutzer H, Psaras T, Grossmann A et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Acta Radiologica 2000;41:446-52.
12. Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ, Hutchins G et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005;104:570-9. (Pubitemid 41022815)
13. 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma. J Nucl Med 2003;45:1323-7. (Pubitemid 47618530)
14. Crippa F, Leutner MM, Belli F, Gallino F, Grecco M, Pilotti S et al. Which kinds of lymph node metastases can FDG-PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491-4.
15. 15O-water using compartment and non-compartment analysis. J Nucl Med 2001;42:248-56. (Pubitemid 32150515)
16. 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. Cancer Research 1990;50:904s-8s.
17. Eary JF, Schroff RW, Abrams PG, Fritzberg AR, Morgan AC, Kasina D et al. Successful imaging of malignant melanoma with technetium-99m labeled monoclonal antibodies. J Nucl Med 1988;30:25-32.
18. Maffioli L, Mascheroni L, Mongioj V, Gasparini M, Baldini MT, Seregni E et al. Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). J Nucl Med 1994;35:1741-7.
19. Oltmanns D, Eisenhut M, Mier W, Haberkorn U. Benzamides as melanotropic carriers for radioisotopes, metals, cytotoxic agents and as enzyme inhibitors. Current Medicinal Chemistry 2009;16:2086-94.
20. Ren G, Miao Z, Liu H, Jiang L, Limpa-Amara N, Mahmood A et al. Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med 2009;50:1692-9.
21. Siegrist W, Solca F, Stutz S, Giuffre L, Carrel S, Girard J et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Research 1989;49:6352-8.
22. Miao Y, Whitener D, Feng W, Owen NK, Chen J-Q, Quinn TP. Evaluation of the human melanoma targeting properties of radiolabeled α-melanocyte stimulating hormone peptide analogues. Bioconjugate Chem 2003;14:1177-84.
23. Lerner AB, McGuire JS. Effect of alpha- and betamelanocyte stimulating hormones on the skin colour of man. Nature 1961;189:176-9.
24. Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007;445:843-50.
25. Sawyer TK, Staples DJ, Catrucci AML, Hadley ME, Al-Obeeidi FA, Cody WL et al. α-Melanocyte stimulating hormone message and inhibitory sequences: Comparative structure activity studies on melanocytes. Peptides 1990;11:351-7.
26. Cone RD, Lu D, Koppula S, Vage D-I, Klungland H, Boston B et al. The melanocortin receptors: Agonists, Antagonists, and the hormonal control of pigmentation. Recent Progress in Hormone Research 1996;51:287-317.
27. Hruby VJ, Sharma SD, Toth K, Jaw JY, al-Obeidi F, Sawyer TK et al. Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann N Y Acad Sci 1993;680:51-63.
28. 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor targeting properties. J Nucl Med 2001;42:1847-55.
29. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 2002;43:1699-706.
30. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004;45:116-23.
31. Hruby VJ, Sawyer TK, Yang YCS, Bergman MD, Hadley ME, Heward CB. Synthesis and structure-function studies of melanocyte stimulating hormone analogues modified in the 2 and 4(7) positions: Comparison of activities on frog skin melanophores and melanoma adenylate cyclase. J Med Chem 1980;23:1432-7.
32. 111In labeled DOTA conjugated rhenium cyclized a-MSH analogs. J Med Chem 2002;45:3048-56.
33. 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem 2008;19:539-47.
34. 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide. Nucl Med Biol 2009;36:267-76.
35. Cheng Z, Chen J, Quinn TP, Jurisson SS. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res 2004;64:1411-8.
36. Yang J, Guo H, Gallazzi F, Padilla RS, Berwick M, Miao Y. Evaluation of a novel RGD-conjugated alpha-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug Chem 2009;20:1634-42.
37. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MN, Heward CE, Burnett JB et al. 4-Norleucine, 7-D-phenylalanine-•-melanocyte-stimulating hormone: A highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980;77:5754-8.
38. Cody WL, Mahoney M, Knittel JJ, Hruby VJ, Castrucci AM, Hadley ME. Cyclic melanotropins. 9. 7-D-Phenylalanine analogues of the active-site sequence. J Med Chem 1985;28:583-8.
39. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem 1989;32:2555-61.
40. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA 1998;95:12814-8.
41. Haskell-Luevano C, Sawyer TK, Hendrata S, North C, Panahinia L, Stum M et al. Truncation studies of alpha-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity. Peptides 1996;17:995-1002.
42. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 1992;257:1248-51.
43. Abdel-Malek ZA. Melanomcortin receptors: their functions1 and regulation by physiological agonists and antagonists. Cell Mol Life Sci 2001;58:434-41.
44. Nikolics K, Teplan I, Medzihradszky K. Synthesis of α-melanotropin labelled with tritium on the tyrosine residue, via the dibromo intermediate. J Labelled Compounds Radiopharm 1976;12:163-71.
45. Buckley DI, Ramachandran J. Preparation of tritiated α-melanotropin with high specific activity. Int J Pept Protein Res 1981;17:514-8.
46. 2: a superpotent melanotropin with prolonged biological activity. Life Sci 1984:34:977-84.
47. Eberle AN. The melanotropins: chemistry, physiology and mechanisms of action. Basel: Karger; 1988.
48. Eberle AN, Froidevaux S. Radiolabeled α-melanocyte-stimulating hormone analogs for receptor mediated targeting of melanoma: from tritium to indium. J Mol Recognition 2003;16:248-54. (Pubitemid 37240463)
49. Eberle AN, Verin VJ, Solca F, Siegrist W, Kuenlin C, Bagutti C et al. Biologically active monoiodinated α-MSH derivatives for receptor binding studies using human melanoma cells. J Recept Res 1991;11:311-22.
50. Siegrist W, Oestreicher M, Stutz S, Girard J, Eberle AN. Radioreceptor assay for α-MSH using mouse B16 melanoma cells. J Recept Res1988;8:323-43.
51. Tatro JB, Atkins MB, Mier JW, Hardarson S, Wolfe H, Smith T et al. Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest 1990;85:1825-32. (Pubitemid 20192956)
52. 7-α- MSH binding sites in rat brain. Ann NY Acad Sci 1993;680:652-4.
53. Garg PK, Alston KL, Welsh PC, Zalutsky MR. Enhanced binding and inertness to dehalogenation of α-melanotropic peptides labeled using N-succinimidyl-3-iodobenzoate. Bioconjugate Chem 1996;7:233-9.
54. 7]-α-MSH, an α-melanocyte stimulating hormone analog. Nucl Med Biol 1997;24:171-8.
55. Zwanzinger D, Beck-Sickinger AG. Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr Pharm Design 2008;14:2385-400.
56. Shuang L. Bifunctional coupling agents for radiolabeleing of biomolecules and target specific delivery of metallic radionuclides. Adv Drug Delivery Rev 2008;60:1347-70.
57. Giblin MF, Jurisson SS, Quinn TP. Synthesis and characterization of rhenium-complexed α-melanotropin analogs. Bioconjugate Chem 1997;8:347-53.
58. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol 1999;26:687-93.
59. Bard DR, Knight CG, Page-Thomas DP. A chelating derivative of α-melanocyte stimulating hormone as a potentinal imagin agent for malignant melanoma. Br J Canc 1990;62:919-22.
60. Wright EP, Bard DR, Maughan TS, Knight CG, Page-Thomas DP. The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol 1992;65:112-8.
61. 3-labeled pyrazolyl-α-melanocyte stimulating hormone analog conjugate for melanoma targeting. Nucl Med Biol 2008;35:91-9.
62. 99mtechnetium-labeled cyclic α-melanocyte stimulating hormone peptide analogues. Cancer Research 2000;60:5649-58.
63. 111In- labeled α-melanocyte stimulation hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med 2007;48:73-80. (Pubitemid 47555378)
64. 99mTc(CO)3]+: effect of cyclization on tumor-seeking properties. J Biol Inorg Chem 2008;13:449-59.
65. Czernin J. Clinical applications of FDG-PET in oncology. Acta Medica Australia 2002;29:162-70.
66. 64Cu- labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem 2007;18:765-72. (Pubitemid 47010796)
67. 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med 2007;48:987-94. (Pubitemid 46909928)
68. 11), a cyclic peptide analogue of a-MSH. J Med Chem 2005;48:2985-92.
69. Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Vavere AL et al. Ga-68 labeled DOTA-rhenium cyclized a-MSH analog for imaging of malignant melanoma. Nucl Med Biol 2007;34:945-53.
70. 68Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl Med Biol 2009;36:505-13.
71. 64Cu-labled rhenium-cyclized a-MSH peptide analogs using a cross-bridged cyclam chelator. J Nucl Med 2007;48:64-72. (Pubitemid 47555377)
72. 18F-labeled metallopeptides. J Nucl Med 2009;50:1865-72.
73. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem 2000;7:971-94.
74. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: production and decay property consideration. J Nucl Med 1991;32:174-85.
75. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW et al. A powerful new tool for receptormediated radionuclide therapy. Eur J Nucl Med 1997;24:792-5. (Pubitemid 27356860)
76. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-8.
77. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-33.
78. Hoefnagel CA. Radionuclide therapy revisited. Eur J Nucl Med 1991;18:408-31.
79. Brechbiel MW. Targeted α-therapy: past present and future. Dalton Trans 2007 21;43:4918-28.
80. Ginj M, Hinn K, Tschumi S, Schultz S, Maecke H. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using Auger electron emitters. J Nucl Med 2005;46:2097-103. (Pubitemid 46657459)
81. Schubiger PA, Alberto R, Smith A. Vehicles, chelators and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug Chem 1996;7:165-79.
82. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537-40. (Pubitemid 33063927)
83. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW et al. Melanoma therapy via peptide-targeted alpha-radiation. Clinical Cancer Res 2005;11:5616-21.
84. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-40. (Pubitemid 34311079)
85. Teuissen JJM, Kwekkeboom DJ, De Jong M, Esser JP, Valkema R, Krenning EP. Peptide receptor radionuclide therapy. Best Pract ResClin Gastroenterol 2005;19:595-616.
86. Larsen RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of Astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells. Radiat Res 1998;149:155-62.
87. 188Re labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 2002;101:480-7.
88. 188Re labeled α-melanocyte stimulating hormone peptide analogue in murine and human melanoma-bearing mouse models. J Nucl Med 2005;46:121-9.
89. 177Lu labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol 2005;32:485-93.
90. 177Lu labeled DOTA conjugated α-melanocyte stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm 2007;22:333-41.
91. 213Bi and their decay chain related radionuclides, for therapy applications. Chem Rev 2001;101:2019-36.
92. Acher RN, Friedman AM, Hines JJ. An improved generator for the production of Pb-212 and Bi-212 from Ra-224. Appl Radiat Isot 1988;39:283-6.
93. Capello A, Krenning EP, Bernard BF, Breeman WA, van Hagen MP, de Jong M. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med 2004;45:1716-20.
94. Lens MD, Dawes M. Global perspective on contemporary epidemiological trends of cutaneous malignant melanoma. Br J Derm 2004;150:179-85.
95. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131-49.
96. 7]-α-MSH in B16 melanoma cells. Int J Biochem Cell Biol 1996;28:1223-32. (Pubitemid 27033138)
97. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers, Arch Dermatol 2004;140:827-35. (Pubitemid 38917851)
98. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind crossover placebo-controlled study, J Urol 1998;160:389-93. (Pubitemid 29476684)
99. 203Pb-labeled a-melanocyte stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med 2008;49:823-9.